Infant, Newborn, Diseases D007232

Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Infant, Newborn, Diseases

Description

Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.   MeSH

Subtype Terms (32)

Amniotic Band Syndrome
 

Anemia, Neonatal
5 drugs (1 approved, 4 experimental)

Asphyxia Neonatorum
3 approved drugs

Birth Injuries
1 approved drug

Colic
36 drugs (13 approved, 23 experimental)

Congenital Bone Marrow Failure Syndromes
7 drugs (5 approved, 2 experimental)

Congenital Hyperinsulinism
17 drugs (13 approved, 4 experimental)

Cystic Fibrosis
293 drugs (140 approved, 153 experimental)

Epilepsy, Benign Neonatal
1 experimental drug

Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)

Hernia, Umbilical
7 drugs (6 approved, 1 experimental)

Hydrophthalmos
 

Hyperbilirubinemia, Neonatal
10 drugs (5 approved, 5 experimental)

Hyperostosis, Cortical, Congenital
 

Ichthyosis
13 drugs (6 approved, 7 experimental)

Infant, Premature, Diseases
84 drugs (53 approved, 31 experimental)

Meconium Aspiration Syndrome
7 drugs (2 approved, 5 experimental)

Mobius Syndrome
 

Neonatal Abstinence Syndrome
15 drugs (7 approved, 8 experimental)

Neonatal Sepsis
37 drugs (24 approved, 13 experimental)

Nystagmus, Congenital
1 experimental drug

Ophthalmia Neonatorum
3 drugs (1 approved, 2 experimental)

Persistent Fetal Circulation Syndrome
10 drugs (9 approved, 1 experimental)

Rothmund-Thomson Syndrome
 

Sclerema Neonatorum
 

Severe Combined Immunodeficiency
39 drugs (23 approved, 16 experimental)

Syphilis, Congenital
 

Thanatophoric Dysplasia
 

Thrombocytopenia, Neonatal Alloimmune
 

Toxoplasmosis, Congenital
3 drugs (2 approved, 1 experimental)

Vitamin K Deficiency Bleeding
1 approved drug

Wolman Disease
14 drugs (11 approved, 3 experimental)


Phase 4 Indicated Drugs (1)

Phase 2 Indicated Drugs (1)

Other Experimental Indicated Drugs (2)


Organization Involved with Phase 4 Indications (2)

Organization Involved with Phase 3 Indications (55)

Organization Involved with Phase 2 Indications (3)

Organization Involved with Other Experimental Indications (3)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.